
Sign up to save your podcasts
Or
In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer’s, and a novel approach for managing uncomfortable neuropathic symptoms.
4.7
1919 ratings
In this week’s podcast, Neurology Today’s editor-in-chief discusses the increased use of antipsychotics during the pandemic and an associated greater risk for dementia, determining the best biomarkers when considering lecanemab for Alzheimer’s, and a novel approach for managing uncomfortable neuropathic symptoms.
130 Listeners
7,676 Listeners
285 Listeners
319 Listeners
45 Listeners
494 Listeners
14 Listeners
186 Listeners
515 Listeners
132 Listeners
320 Listeners
182 Listeners
363 Listeners
2 Listeners
77 Listeners